Drugs & Targets FDA seeks academic and patient advocate research partners for oncology data analysis September 12, 2025Vol.51 No.33
Drugs & Targets FDA approves expanded indication for Avtozma intravenous formulation in cytokine release syndrome September 05, 2025Vol.51 No.32
Drugs & Targets FDA grants breakthrough designation for Rina-S in advanced endometrial cancer September 05, 2025Vol.51 No.32
Drugs & Targets ColoAlert colorectal screening test receives approval in Switzerland September 05, 2025Vol.51 No.32
Drugs & TargetsFree FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma August 08, 2025Vol.51 No.31
Drugs & Targets FDA grants priority review for Imfinzi in gastric and GEJ cancer August 01, 2025Vol.51 No.30
Drugs & Targets EC approves Sarclisa in combination with VRd for transplant-eligible newly diagnosed MM August 01, 2025Vol.51 No.30
Drugs & Targets FDA extends review period for Blenrep combinations after unfavorable ODAC vote, EU approval July 25, 2025Vol.51 No.29By Jacquelyn Cobb
Drugs & Targets FDA issues CRL for RP1+ nivolumab BLA for treatment of advanced melanoma July 25, 2025Vol.51 No.29
